PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Progress Toward Measles Elimination - Bangladesh, 2000-2016.

Abstract In 2013, at the 66th session of the Regional Committee of the World Health Organization (WHO) South-East Asia Region (SEAR), a regional goal was established to eliminate measles and control rubella and congenital rubella syndrome* by 2020 (1). WHO-recommended measles elimination strategies in SEAR countries include 1) achieving and maintaining ≥95% coverage with 2 doses of measles-containing vaccine (MCV) in every district, delivered through the routine immunization program or through supplementary immunization activities (SIAs)(†); 2) developing and sustaining a sensitive and timely measles case-based surveillance system that meets targets for recommended performance indicators; and 3) developing and maintaining an accredited measles laboratory network (2). In 2014, Bangladesh, one of 11 countries in SEAR, adopted a national goal for measles elimination by 2018 (2,3). This report describes progress and challenges toward measles elimination in Bangladesh during 2000-2016. Estimated coverage with the first MCV dose (MCV1) increased from 74% in 2000 to 94% in 2016. The second MCV dose (MCV2) was introduced in 2012, and MCV2 coverage increased from 35% in 2013 to 93% in 2016. During 2000-2016, approximately 108.9 million children received MCV during three nationwide SIAs conducted in phases. During 2000-2016, reported confirmed measles incidence decreased 82%, from 34.2 to 6.1 per million population. However, in 2016, 56% of districts did not meet the surveillance performance target of ≥2 discarded nonmeasles, nonrubella cases(§) per 100,000 population. Additional measures that include increasing MCV1 and MCV2 coverage to ≥95% in all districts with additional strategies for hard-to-reach populations, increasing sensitivity of measles case-based surveillance, and ensuring timely transport of specimens to the national laboratory will help achieve measles elimination.
PMID
Related Publications

Progress toward measles elimination--Western Pacific Region, 2009-2012.

Progress toward measles elimination—Philippines, 1998-2014.

Progress Toward Measles Elimination - African Region, 2013-2016.

Progress Toward Measles Elimination - South-East Asia Region, 2003-2013.

Progress Toward Measles Elimination - Nepal, 2007-2014.

Authors

Mayor MeshTerms

Disease Eradication

Population Surveillance

Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 28727678
OWN - NLM
STAT- MEDLINE
DA  - 20170720
DCOM- 20170724
LR  - 20170724
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 66
IP  - 28
DP  - 2017 Jul 21
TI  - Progress Toward Measles Elimination - Bangladesh, 2000-2016.
PG  - 753-757
LID - 10.15585/mmwr.mm6628a3 [doi]
AB  - In 2013, at the 66th session of the Regional Committee of the World Health
      Organization (WHO) South-East Asia Region (SEAR), a regional goal was established
      to eliminate measles and control rubella and congenital rubella syndrome* by 2020
      (1). WHO-recommended measles elimination strategies in SEAR countries include 1) 
      achieving and maintaining >/=95% coverage with 2 doses of measles-containing
      vaccine (MCV) in every district, delivered through the routine immunization
      program or through supplementary immunization activities (SIAs)dagger; 2)
      developing and sustaining a sensitive and timely measles case-based surveillance 
      system that meets targets for recommended performance indicators; and 3)
      developing and maintaining an accredited measles laboratory network (2). In 2014,
      Bangladesh, one of 11 countries in SEAR, adopted a national goal for measles
      elimination by 2018 (2,3). This report describes progress and challenges toward
      measles elimination in Bangladesh during 2000-2016. Estimated coverage with the
      first MCV dose (MCV1) increased from 74% in 2000 to 94% in 2016. The second MCV
      dose (MCV2) was introduced in 2012, and MCV2 coverage increased from 35% in 2013 
      to 93% in 2016. During 2000-2016, approximately 108.9 million children received
      MCV during three nationwide SIAs conducted in phases. During 2000-2016, reported 
      confirmed measles incidence decreased 82%, from 34.2 to 6.1 per million
      population. However, in 2016, 56% of districts did not meet the surveillance
      performance target of >/=2 discarded nonmeasles, nonrubella cases section sign
      per 100,000 population. Additional measures that include increasing MCV1 and MCV2
      coverage to >/=95% in all districts with additional strategies for hard-to-reach 
      populations, increasing sensitivity of measles case-based surveillance, and
      ensuring timely transport of specimens to the national laboratory will help
      achieve measles elimination.
FAU - Khanal, Sudhir
AU  - Khanal S
FAU - Bohara, Rajendra
AU  - Bohara R
FAU - Chacko, Stephen
AU  - Chacko S
FAU - Sharifuzzaman, Mohammad
AU  - Sharifuzzaman M
FAU - Shamsuzzaman, Mohammad
AU  - Shamsuzzaman M
FAU - Goodson, James L
AU  - Goodson JL
FAU - Dabbagh, Alya
AU  - Dabbagh A
FAU - Kretsinger, Katrina
AU  - Kretsinger K
FAU - Dhongde, Deepak
AU  - Dhongde D
FAU - Liyanage, Jayantha
AU  - Liyanage J
FAU - Bahl, Sunil
AU  - Bahl S
FAU - Thapa, Arun
AU  - Thapa A
LA  - eng
PT  - Journal Article
DEP - 20170721
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Measles Vaccine)
SB  - IM
MH  - Adolescent
MH  - Bangladesh/epidemiology
MH  - Child
MH  - Child, Preschool
MH  - *Disease Eradication
MH  - Humans
MH  - Immunization Programs
MH  - Incidence
MH  - Infant
MH  - Measles/*epidemiology/*prevention & control
MH  - Measles Vaccine/administration & dosage
MH  - Measles virus/genetics/isolation & purification
MH  - *Population Surveillance
MH  - Vaccination/statistics & numerical data
EDAT- 2017/07/21 06:00
MHDA- 2017/07/25 06:00
CRDT- 2017/07/21 06:00
AID - 10.15585/mmwr.mm6628a3 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2017 Jul 21;66(28):753-757. doi:
      10.15585/mmwr.mm6628a3.